About Colin Walsh
Colin Walsh is a board member at AirNexis Therapeutics.
Colin Walsh reports to the SEC as a director of 2 public companies: Attovia Therapeutics (ATTO) and Elevation Oncology (ELEV).
Colin Walsh first appears on SEC filings in 2021.
Experience
This experience comes from Colin Walsh's profile and from SEC filings. For roles taken from filings, the years are when the filings name Colin Walsh in the role, so the role may have started earlier or lasted longer.
AirNexis Therapeutics, Inc. Current
Board Member
2026 – Present · Palo Alto, CA
Develops an inhaled treatment for people with chronic obstructive pulmonary disease.
BT
Beacon Therapeutics Current
Board Member
2025 – Present
AI
Attovia Therapeutics, Inc. Current
Director
2024 – Present · Public company (ATTO)
GS
Goldman Sachs Current
Managing Director - Life Sciences Investing
2023 – Present
VI
Vicebio
Board Member
2024 – 2025
EI
Elevation Oncology, Inc.
Director
2019 – 2023 · Public company (ELEV)
AT
Abdera Therapeutics
Board Member
2023
EB
Entact Bio
Board Member
2021 – 2023
EI
Element Science, Inc.
Board Member
2021 – 2023
KI
Korro Bio, Inc.
Board Member
2020 – 2023
QU
Qiming Venture Partners USA
Partner
2019 – 2023
VB
Ventyx Biosciences
Board Observer
2021
II
Icosavax, Inc.
Board Observer
2019 – 2021
NA
NanoDimension
Vice President
2014 – 2019
PI
Precision NanoSystems, Inc.
Strategy & Business Development
2012 – 2015
UF
University of California, San Francisco
NSF Graduate Research Fellow
2008 – 2012
UA
University of Massachusetts Amherst
Research Assistant
2005 – 2007
Key Colleagues at Startups
The people Colin Walsh works with at each company, as listed on that company's latest Form D.
AirNexis Therapeutics, Inc. · Form D, Mar 9, 2026
Anna Chen
Board Member
Evan Caplan
Board Member
JL
James Li
Chair of the Board
Jill Carroll
Board Member
MF
Maria Fardis
CEO and director